DRDR:LSE:LSE-iShares Healthcare Innovation UCITS ETF USD (Acc) (GBX)

ETF | Others |

Last Closing

USD 595.5

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.06M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-16 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

N/A

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 584.80B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 583.82B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

N/A

USD 218.91B
0QZ3:LSE Qualcomm Inc.

N/A

USD 202.26B

ETFs Containing DRDR:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.63% 29% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.63% 30% F 39% F
Trailing 12 Months  
Capital Gain 12.17% 56% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.17% 57% F 56% F
Trailing 5 Years  
Capital Gain 24.75% 51% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.75% 52% F 59% D-
Average Annual (5 Year Horizon)  
Capital Gain 2.82% 37% F 46% F
Dividend Return 2.82% 36% F 45% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 20.68% 32% F 48% F
Risk Adjusted Return 13.64% 33% F 45% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.